Biotech Values

[DewDiligence]

You could make the same argument about drug development in general - clearly most drugs are going to fail.

It’s a matter of degree. Due to the overabundant supply of drug candidates in cancer, the probability of commercial success for a typical drug candidate in cancer is smaller than in most other areas of biotech.